The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Heterogeneity in Primary Structure, Post-Translational Modifications, and Germline Gene Usage of Nine Full-Length Amyloidogenic κ1 Immunoglobulin Light Chains
Open accessAbstract
Immunoglobulin light chain amyloidosis is a protein misfolding disease in which a monoclonal immunoglobulin (Ig) light chain (LC) with a critically folded beta-conformation self-aggregates to form highly ordered, nonbranching amyloid fibrils. The insoluble nature of amyloid fibrils ultimately results in the extracellular deposition of the LC in tissues and organs throughout the body. Structural features that confer amyloidogenic properties on an Ig LC likely include amino acid sequence variations and post-translational modifications, but the specific natures of these changes remain to be defined. As part of an exploration of the effective range of amyloidogenic modifications, this study details the structural and genetic analyses of nine kappa1 LC proteins. Urinary LCs were purified by size exclusion chromatography using FPLC, and structural analyses were performed by electrospray ionization, matrix-assisted laser desorption/ionization, and tandem mass spectrometry. RT-PCR amplification, cloning, and sequencing of the monoclonal LC genes were accomplished using bone marrow-derived mRNA. Clinical data were reviewed retrospectively. Characterization of the urinary kappa1 LCs revealed extensive post-translational modification in all proteins, in addition to somatic mutations expected on the basis of results from genetic analyses. Post-translational modifications included disulfide-linked dimerization, S-cysteinylation, glycosylation, fragmentation, S-sulfonation, and 3-chlorotyr…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In other disease areas, including organ fibrosis, several examples exist in which a mutation at one site can affect PTM profiles elsewhere on the protein 53-55 .”
From How many human proteoforms are there? (2018) · cites this paper as [53]
Citations
Cites
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385 · cited 1×
“Proteins were initially separated by SDS—PAGE, electrophoretically transferred to nitrocellulose, and then visualized by antibody-linked staining (28,29).”
MethodWeber, K., & Osborn, M. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94333-4 · Cited by 20,298 · cited 1×
“Electrophoresis on 10-15% gradient polyacrylamide gels (26,27) was performed using an automated Phast system (GE Healthcare Bio-Sciences).”
MethodMolecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920 · cited 4×
“(4) Fragmentation—Evidence of extensive fragmentation was found in one LC protein sample.”
BackgroundInfluentialTowbin, H., Staehelin, T., & Gordon, J. (1992) · PubMed · Cited by 800
Skinner, M., Sanchorawala, V., Seldin, D. C., Dember, L. M., Falk, R. H., Berk, J. L., Anderson, J. J., O'Hara, C., Finn, K. T., Libbey, C. A., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-2-200401200-00008 · Cited by 618 · cited 2×
“Although disease presentation usually involves a relatively minor bone marrow abnormality, AL is devastating in the usually massive extent of organ system amyloid deposits and in the short survival that accompanies the disease (2).”
BackgroundSelf-citationElimination of Oxidative Degradation during the per-O-Methylation of Carbohydrates
Ciucanu, I., & Costello, C. E. (2003) · Journal of the American Chemical Society · doi:10.1021/ja035660t · Cited by 287 · cited 2×
“The PNGase F-released glycans were permethylated using a standard protocol (31, 33).”
MethodSelf-citationA Three-Stage Kinetic Model of Amyloid Fibrillation
Lee, C.-C., Nayak, A., Sethuraman, A., Belfort, G., & McRae, G. J. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.098608 · Cited by 278 · cited 1×
“The prevailing paradigm for amyloidogenesis holds that the precursor amyloid protein becomes structurally destabilized, transitions through a series of intermediate conformations, and ultimately adopts a non-native assembly that favors selfaggregation (12-17).”
Wogulis, M., Wright, S., Cunningham, D., Chilcote, T., Powell, K., & Rydel, R. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2381-04.2005 · Cited by 233 · cited 1×
“The prevailing paradigm for amyloidogenesis holds that the precursor amyloid protein becomes structurally destabilized, transitions through a series of intermediate conformations, and ultimately adopts a non-native assembly that favors selfaggregation (12-17).”
BackgroundBellotti, V., Mangione, P., & Merlini, G. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4248 · Cited by 190
Bizzozero, O. A., DeJesus, G., Callahan, K., & Pastuszyn, A. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20587 · Cited by 134 · cited 1×
“S-cysteinylation of other proteins has been linked to elevated levels of homocysteine, a biomolecule which is converted to cysteine in oxidizing environments (40-42).”
Background
Research works printed but not linked: 40
- Falk R. H., 1997, N. Engl. J. Med., 337
- Falk R. H., 2000, 45, 107−137.
- Lansbury P. T., Jr., 1999, Proc. Natl. Acad. Sci. U.S.A. 96
- Stevens F. J., 1995, Biochemistry 34, 10697−10702.
- Liepnieks J. J., 1990, Mol. Immunol. 27, 481−485.
- Myran T., 2004, Amyloid 11, 109−112.
- Solomon A., 1998, Proc. Natl. Acad. Sci. U.S.A. 95
- Hurshman A. R., 2004, Biochemistry 43, 7365−7381.
- Kelly J. W., 2000, Nat. Struct. Biol. 7, 824−826.
- Konno T., 2001, Protein Sci. 10
- Lee C. C., 2007, Biophys. J., 92
- Thirumalai D., 2003, Curr. Opin. Struct. Biol. 13, 146−159.
- Liao R., 2001, Circulation 104, 1594−1597.
- Brenner D. A., 2004, Circ. Res. 94, 1008−1010.
- Omtvedt L. A., 2000, Amyloid 7, 227−244.
- Stevens F. J., 2000, Amyloid 7, 200−211.
- Prokaeva T., 2007, Arthritis Rheum. (in press).
- Lim A., 2001, Anal. Biochem., 295, 56
- Laemmli U. K., 1970, Nature 227, 680−685.
- Jagersten C., 1988, Electrophoresis 9, 662−665.
- Conboy J. J., 1992, Biol. Mass Spectrom. 21, 397−407.
- Giudicelli V., 2004, Nucleic Acids Res. 32, W435−440.
- Reinhold V. N., 1995, Anal. Chem. 67, 1772−1784.
- Rogozin I. B., 1992, Biochim. Biophys. Acta, 1171, 18
- Abraham R. S., 2002, Clin. Chem. 48
- Grey H. M., 1968, Clin. Exp. Immunol. 3, 277−285.
- Peterson P. A., 1971, Eur. J. Clin. Invest., 1
- Schormann N., 1995, Proc. Natl. Acad. Sci. U.S.A. 92
- Bar-Or D., 2005, Prenatal Diagn. 25, 245−249.
- Chen W., 1999, J. Exp. Med., 189
- Watarai H., 2000, Proc. Natl. Acad. Sci. U.S.A. 97
- Foss G. S., 1998, Scand. J. Immunol., 47
- Milstein C. P., 1971, Biochem. J., 121
- Toft K. G., 1985, Biol. Chem. Hoppe-Seyler 366, 617−625.
- Dimroth P., 1982, Biosci. Rep. 2, 849−860.
- Okamura T., 1998, J. Nutr. Sci. Vitaminol., 44
- Abraham R. S., 2003, Blood 101, 3801−3808.
- Gallo G., 1996, Am. J. Pathol., 148
- Schiffer M., 1996, Am. J. Pathol., 148
- Abbreviations, immunoglobulin
Cited by
How many human proteoforms are there?
Aebersold, R., Agar, J. N., Amster, I. J., Baker, M. S., Bertozzi, C. R., Boja, E. S., Costello, C. E., Cravatt, B. F., Fenselau, C., Garcia, B. A., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2576 · Cited by 907
Self-citationAmyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue
Lavatelli, F., Perlman, D. H., Spencer, B., Prokaeva, T. B., McComb, M. E., Théberge, R., Connors, L. H., Bellotti, V., Seldin, D. C., Merlini, G., et al. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700545-mcp200 · Cited by 153
Self-citationGuan, J., Mishra, S., Qiu, Y., Shi, J., Trudeau, K. M., Las, G., Liesa, M., Shirihai, O. S., Connors, L. H., Seldin, D. C., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404190 · Cited by 141
“Antibodies were obtained from Santa Cruz Biotechnology (TFEB), Cell signaling Technology (total and phosphorylated S6 Kinase, COX4), MBL (LC3), R&D Systems (GAPDH), Sigma (b-actin), Abcam (active caspase 3) and Abnovo (p62).”
MethodInfluentialSelf-citationThe utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinic
Milani, P., Murray, D. L., Barnidge, D. R., Kohlhagen, M., Mills, J. R., Merlini, G., Dasari, S., & Dispenzieri, A. A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24772 · Cited by 135
Treatment of Immunoglobulin Light Chain Amyloidosis
Dispenzieri, A. A., Buadi, F. K., Kumar, S. K., Reeder, C. B., Sher, T., Lacy, M. Q., Kyle, R. A., Mikhael, J. R., Roy, V., Leung, N., et al. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.009 · Cited by 128
What do I need to know about immunoglobulin light chain (AL) amyloidosis?
Dispenzieri, A. A., Gertz, M. A., & Buadi, F. K. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.03.001 · Cited by 117
Harvey, D. J. (2010) · Mass Spectrometry Reviews · doi:10.1002/mas.20265 · Cited by 105
Harvey, D. J. (2011) · Mass Spectrometry Reviews · doi:10.1002/mas.20333 · Cited by 101
Dispenzieri, A. A., Larson, D. R., Rajkumar, S. V., Kyle, R. A., Kumar, S. K., Kourelis, T., Arendt, B. K., Willrcih, M., Dasari, S., & Murray, D. L. (2020) · Leukemia · doi:10.1038/s41375-020-0940-8 · Cited by 95
Kumar, S., Murray, D. L., Dasari, S., Milani, P., Barnidge, D. R., Madden, B. J., Kourelis, T., Arendt, B. K., Merlini, G., Ramírez-Alvarado, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0194-x · Cited by 91
Immunoglobulin Free Light Chain Dimers in Human Diseases
Kaplan, B., Livneh, A., & Sela, B. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.65 · Cited by 88
Current perspectives on cardiac amyloidosis
Guan, J., Mishra, S., Falk, R. H., & Liao, R. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00815.2011 · Cited by 81
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity
Guan, J., Mishra, S., Shi, J., Plovie, E. R., Qiu, Y., Cao, X., Gianni, D., Jiang, B., del Monte, F., Connors, L. H., et al. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0378-5 · Cited by 76
“LC isolated from AL amyloid patients and Con-LC, nonamyloidogenic LC isolated from non-amyloidosis multiple myeloma patients), were purified from urine collection in collaboration with Boston University Amyloid Treatment and Research Program [5].”
Self-citationFibril protein fragmentation pattern in systemic AL‐amyloidosis
Enqvist, S., Sletten, K., & Westermark, P. (2009) · The Journal of Pathology · doi:10.1002/path.2607 · Cited by 70
Serebryany, E., Yu, S., Trauger, S. A., Budnik, B., & Shakhnovich, E. I. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004551 · Cited by 65
Free light chain monomers in the diagnosis of multiple sclerosis
Kaplan, B., Aizenbud, B. M., Golderman, S., Yaskariev, R., & Sela, B. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.09.002 · Cited by 61
Ren, R., Hong, Z., Gong, H., Laporte, K., Skinner, M. M., Seldin, D. C., Costello, C. E., Connors, L. H., & Trinkaus‐Randall, V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149575 · Cited by 58
Self-citationMonitoring free light chains in serum using mass spectrometry
Barnidge, D. R., Dispenzieri, A. A., Merlini, G., Katzmann, J. A., & Murray, D. L. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0917 · Cited by 51
Light Chain Amyloidosis – Current Findings and Future Prospects
Baden, E. M., Sikkink, L. A., & Ramírez-Alvarado, M. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309789351949 · Cited by 47
Transient disorder along pathways to amyloid
Morgan, G. J. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106711 · Cited by 45
Lavatelli, F., Brambilla, F., Valentini, V., Rognoni, P., Casarini, S., Silvestre, D. D., Perfetti, V., Palladini, G. O., Sarais, G., Mauri, P., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.12.012 · Cited by 45
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis
Nevone, A., Girelli, M., Mangiacavalli, S., Paiva, B., Milani, P., Cascino, P., Piscitelli, M., Speranzini, V., Cartia, C. S., Benvenuti, P., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01599-w · Cited by 45
Antibodies gone bad – the molecular mechanism of light chain amyloidosis
Absmeier, R. M., Rottenaicher, G. J., Svilenov, H. L., Kazman, P., & Büchner, J. (2022) · FEBS Journal · doi:10.1111/febs.16390 · Cited by 43
Kaplan, B., Ramírez-Alvarado, M., Sikkink, L. A., Golderman, S., Dispenzieri, A. A., Livneh, A., & Gallo, G. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07522.x · Cited by 41
Sidana, S., Tandon, N., Gertz, M. A., Dispenzieri, A. A., Ramírez-Alvarado, M., Murray, D. L., Kourelis, T., Buadi, F. K., Kapoor, P., Gonsalves, W. I., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15832 · Cited by 30
“There is also some data to suggest that post-translational modifications that alter the structure of light chains, like glycosylation, also contribute to amyloidogenicity (Omtvedt et al, 2000; Connors et al, 2007; Milani et al, 2017b).”
BackgroundThe Challenge of Systemic Immunoglobulin Light-Chain Amyloidosis (AL)
Palladini, G. O., & Comenzo, R. L. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_22 · Cited by 30
Immunoglobulin Light Chain Systemic Amyloidosis
Dispenzieri, A. A., & Merlini, G. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_15 · Cited by 29
Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang, C., Huang, X., & Li, J. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.03.002 · Cited by 29
Guan, J., Mishra, S., Qiu, Y., Shi, J., Trudeau, K. M., Las, G., Liesa, M., Shirihai, O. S., Connors, L. H., Seldin, D. C., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505318 · Cited by 28
Self-citationNokwe, C. N., Hora, M., Zacharias, M., Yagi, H., Peschek, J., Reif, B., Goto, Y., & Büchner, J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.015 · Cited by 25
Ma, J., Jiang, D., Gong, X., Shao, W., Zhu, Z., Xu, W., & Qiu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-05468-w · Cited by 24
Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
Morgan, G. J., Buxbaum, J. N., & Kelly, J. W. (2021) · Hemato · doi:10.3390/hemato2040042 · Cited by 23
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
Rognoni, P., Lavatelli, F., Casarini, S., Palladini, G. O., Verga, L., Pedrazzoli, P., Valentini, G., Merlini, G., & Perfetti, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076022 · Cited by 22
The Process of Amyloid Formation due to Monoclonal Immunoglobulins
Morgan, G. J., & Wall, J. S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.07.003 · Cited by 21
Oxidative post-translational modifications of an amyloidogenic immunoglobulin light chain protein
Lu, Y., Jiang, Y., Prokaeva, T. B., Connors, L. H., & Costello, C. E. (2016) · International Journal of Mass Spectrometry · doi:10.1016/j.ijms.2016.11.006 · Cited by 19
“Urinary LC protein purification was carried out according to a protocol we have published earlier, with minor modifications (22).”
BackgroundMethodSelf-citationDomain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants
Weber, B., Hora, M., Kazman, P., Pradhan, T., Rührnößl, F., Reif, B., & Büchner, J. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.10.005 · Cited by 19
Determination of Peptide and Protein Disulfide Linkages by MALDI Mass Spectrometry
Yang, H., Liu, N., & Liu, S. (2012) · Topics in current chemistry · doi:10.1007/128_2012_384 · Cited by 18
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma
Schreiner, S., Berghaus, N., Poos, A. M., Raab, M. S., Besemer, B., Fenk, R. R., Goldschmidt, H., Mai, E. K., Müller‐Tidow, C., Weinhold, N., et al. (2024) · Amyloid · doi:10.1080/13506129.2023.2295221 · Cited by 14
“In another study, Conners et al. [30] describes the replacement of D70 with asparagine as an introduction of an N-glycosylation site.”
BackgroundKlimtchuk, E. S., Peterle, D., Bullitt, E., Connors, L. H., Engen, J. R., & Gursky, O. (2023) · Amyloid · doi:10.1080/13506129.2023.2212397 · Cited by 14
“In part 1, we explored two patient-based variants, AL 00-131 and MM 96-100 [10], and their common germline LC, GL 33 (cid:1) 01 (henceforth termed AL1, MM1 and GL1).”
MethodSelf-citationMechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis
Lavatelli, F. (2022) · Hemato · doi:10.3390/hemato3010005 · Cited by 13
Proteomics in protein misfolding diseases
Stoppini, M., Obici, L. P., Lavatelli, F., Giorgetti, S., Marchese, L., Moratti, R., Bellotti, V., & Merlini, G. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.164 · Cited by 13
Light chain editors of anti-DNA receptors in human B cells
Kalinina, O., Wang, Y., Sia, J. K., Radic, M. Z., Cazenave, P., & WEIGERT, M. G. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20122340 · Cited by 12
Amyloidosis - Mechanisms and Prospects for Therapy
Sarantseva, S. V. (2011) · InTech eBooks · doi:10.5772/757 · Cited by 12
Rognoni, P., Mazzini, G., Caminito, S., Palladini, G. O., & Lavatelli, F. (2021) · Medicina · doi:10.3390/medicina57090916 · Cited by 10
“Diverse chemical modifications affecting amyloidogenic LCs have been described over the years through multiple biochemical approaches, such as oxidation [8,63,77], cysteinylation [12,59], deamidation [78] and glycosylation [9,10,73–75,79].”
BackgroundImpact of milieu conditions on the α-lactalbumin glycosylation in the dry state
Cheison, S. C., Josten, E., & Kulozik, U. (2012) · Journal of Food Engineering · doi:10.1016/j.jfoodeng.2012.11.003 · Cited by 9
Sidana, S., Dasari, S., Kourelis, T., Dispenzieri, A. A., Murray, D. L., King, R. L., McPhail, E. D., Ramírez-Alvarado, M., Kumar, S. K., & Gertz, M. A. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003671 · Cited by 8
Davern, S. M., Murphy, C. L., O’Neill, H., Wall, J. S., Weiss, D. T., & Solomon, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.022 · Cited by 8
Sheehan, K., Jeon, H., Corr, S. C., Hayes, J. M., & Mok, K. H. (2024) · The Protein Journal · doi:10.1007/s10930-024-10237-6 · Cited by 7
“Through further analysis of the κ1 amyloidogenic LCs from the urine of AL amyloidosis patients, a high diversity in post translational modifications was identified and included S-cysteinylation, N-glycosylation, and fragmentation [179].”
Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis
Morgan, G. J., Yung, Z., Spencer, B., Sanchorawala, V., & Prokaeva, T. B. (2024) · Pharmaceuticals · doi:10.3390/ph17111542 · Cited by 7
“N-glycosylation N-glycosylation of asparagine residues, which has been observed in many AL-associated LCs [32,34–38], has gained a new prominence recently due to several studies showing that κ LCs from individuals with AL amyloidosis are more likely to be N-glycosylated than κ LCs associated with…”
Self-citationGoldis, R., Kaplan, B., Arad, M., Dispenzieri, A. A., Dasari, S., Kukuy, O. L., Simon, A. J., Dori, A., Stein, E. S., Ziv, T., et al. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0591 · Cited by 7
Advances in proteomic study of cardiac amyloidosis: progress and potential
Lavatelli, F., & Merlini, G. (2016) · Expert Review of Proteomics · doi:10.1080/14789450.2016.1242417 · Cited by 7
Abe, Y., Shibata, H., Oyama, K., & Ueda, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.194 · Cited by 7
Kumar, S., Murray, D. L., Dasari, S., Milani, P., Barnidge, D. R., Madden, B. J., Kourelis, T., Arendt, B. K., Merlini, G., Ramírez-Alvarado, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0405-0 · Cited by 7
Edwards, C. V., Ferri, G. M., Villegas-Galaviz, J., Ghosh, S., Bawa, P., Wang, F., Klimtchuk, E. S., Ajayi, T. B., Morgan, G. J., Prokaeva, T. B., et al. (2025) · Amyloid · doi:10.1080/13506129.2025.2478397 · Cited by 6
“Thereafter, total RNA was extracted and used to synthesise complementary DNA which was then amplified by multiplex polymerase chain reaction, cloned, and sequenced as previously described [37,41].”
Self-citationKukuy, O. L., Kaplan, B., Golderman, S., Volkov, A., Duek, A., Leiba, M., Ben‐Zvi, I., & Livneh, A. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01699-5 · Cited by 4
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis
Nuvolone, M., Palladini, G. O., & Merlini, G. (2015) · Current clinical pathology · doi:10.1007/978-3-319-19294-9_2 · Cited by 4
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis
Nuvolone, M., Palladini, G. O., & Merlini, G. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-389-3_2 · Cited by 4
Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains
Wong, S., West, M. E., & Morgan, G. J. (2023) · Protein Science · doi:10.1002/pro.4871 · Cited by 3
“AL amyloid fibrils are most commonly formed from fragments of light chains, including the variable domain (Connors et al., 2007; Enqvist et al., 2009; Lavatelli et al., 2008).”
BackgroundChen, C., Chen, P., & Fang, X. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22658 · Cited by 3
Pathogenesis of Systemic Amyloidoses
Lavatelli, F., Palladini, G. O., & Merlini, G. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-631-3_4 · Cited by 3
“The presence of fragments of the precursors, instead, is a notorious phenomenon observed in urines of patients with AL amyloidosis [ 43 , 44], while their presence in the circulation in vivo is less well defined.”
BackgroundPeterle, D., Yan, N., Klimtchuk, E. S., Srinivasu, B. Y., Brusic, V., Rhoades, D. J., Wales, T. E., Gursky, O., Kelly, J. W., Engen, J. R., et al. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169917 · Cited by 2
Expression, Function, and Significance of Non B Cell-Derived Immunoglobulin in Haematological System
Wu, L., Xia, M., Wang, C., Yan, H., Gong, X., & Yin, C. C. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-0511-5_15 · Cited by 1
Investigation of amyloid deposition in uterine leiomyoma patients
Liu, J., Zhai, F., Ge, P., Jin-hai, L., Qin, Y., & Sun, X. (2012) · Health · doi:10.4236/health.2012.48083 · Cited by 1
DiCostanzo, A. C., & Ramírez-Alvarado, M. (2011) · InTech eBooks · doi:10.5772/19477
“The two most heavily modified proteins in the aforementioned study (Connors et al., 2007) also included a methionine residue that had been oxidized to methionine sulfoxide.”
Disulfide Exchange and Self-Catalyzed Aggregation in Cataract-Associated Human Gamma-D Crystallin
Serebryany, E., Yu, S., Trauger, S. A., Budnik, B., & Shakhnovich, E. I. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2018.11.1743
Principles of antibody domain integrity
Weber, B. (2018) · mediaTUM (Technical University of Munich)
Mécanismes biochimiques de l'amyloïdose à chaînes légères
Laporte Wolwertz, M. (2016) · Archipel (Université du Québec à Montréal)
Molecular determinants and mechanisms of antibody light chain (AL) amyloidosis
Nokwe Nkumbe, C. (2016)
Schreiner, S. U. (2025) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00037478
Metadata
- Authors
- Connors, L. H., Jiang, Y., Budnik, M., Théberge, R., Prokaeva, T., Bodi, K. L., Seldin, D. C., Costello, C. E., & Skinner, M.
- Affiliations
- Boston University (US)
- Corresponding author
- Connors, Lawreen H.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-16
- Volume
- 46
- Issue
- 49
- Pages
- 14259-14271
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2912213
- OpenAlex
- W1986202137
- Cited by
- 62
- References
- 22
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 5 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 6
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (1s10rr010493-01)
- National Heart, Lung, and Blood Institute (P01HL068705, P01HL68705)
- National Center for Research Resources (S10 RR15942, P41-RR-10888, S10 RR-10493, S10RR015942, P41RR010888)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Keywords
- AL amyloidosis, amyloidogenicity, post-translational modification, germline gene usage, somatic mutations, glycosylation, 3-chlorotyrosine, monoclonal immunoglobulin light chains, protein misfolding, light chain variable region
- MeSH terms
- Adult, Aged, Amino Acid Sequence, Amyloidosis, Chromatography, Gel, Electrophoresis, Polyacrylamide Gel, Female, Humans, Immunoglobulin kappa-Chains, Male, Middle Aged, Protein Processing, Post-Translational, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Spectrometry, Mass, Electrospray Ionization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.